A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing
guidelines and regulations. The company is also working closely with relevant government authorities to schedule the on-site end-use check of its other subsidiary, WuXi Biologics (Shanghai) Co., Ltd., and will commence the UVL delisting process for such entity as soon as the check is ...
(Hong Kong, March 22, 2023) – WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Group”, stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions f
Suzhou, China, April 14, 2020, WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the Euro
WuXi Biologics is a subsidiary of the WuXi AppTec Group with branches in Wuxi, Shanghai and Suzhou. As a platform for innovative companies to realize their dream of developing new drugs, WuXi AppTec is expected to provide world-class integrated biopharma
Hong Kong, China, April 30, 2024 – WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today published its 2023 Environmental, Social and Governance (ESG) Report, highlighting
Business Yao Ming Biotechnology Co., Ltd. is an investment holding company mainly engaged in providing end-to-end solutions and services for biological discovery, development and production to customers in the biologics industry. The company mainly operates its business through two divisions. The Bioph...
development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision...
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The ...
In 2023, Wuxi Biologics Ireland Ltd continued in its start-up phase culminating in its first engineering batches for a client at its Dundalk plant. This resulted in revenue increasing from €16.1 million to €100.2 million. The pretax losses of €86.7 million take account ...